Revolution Medicines (RVMD) Shares Outstanding (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Shares Outstanding (Entity) of $200.2 million for Q1 2026, up 7.47% year-over-year from $186.3 million in Q1 2025, and up 1.61% quarter-over-quarter from $197.0 million in Q4 2025.
Revolution Medicines (RVMD) Shares Outstanding (2019 - 2026) Analysis & Trends
Revolution Medicines' Shares Outstanding (Entity) history runs 8 years deep, the most recent figure standing at $200.2 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 7.47% year-over-year to $200.2 million; the TTM figure through Mar 2026 stood at $200.2 million (up 7.47% YoY), while the FY2025 annual figure was $197.0 million, up 5.97% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $200.2 million, up from $197.0 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $200.2 million in Q1 2026, with the low at $74.2 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $164.9 million (2024), against an average of $141.7 million.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) increased 1.08% in 2022, then soared 64.29% in 2024.
- Revolution Medicines' Shares Outstanding (Entity) stood at $90.4 million in 2022, then climbed by 25.15% to $113.1 million in 2023, then surged by 64.29% to $185.9 million in 2024, then gained by 5.97% to $197.0 million in 2025, then gained by 1.61% to $200.2 million in 2026.
- Business Quant data shows RVMD's Shares Outstanding (Entity) at $200.2 million in Q1 2026, $197.0 million in Q4 2025, and $189.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 720.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 210.89 Mn |
| Mar 31, 2026 | 198.10 Mn |
| Dec 31, 2025 | 190.13 Mn |
| Sep 30, 2025 | 189.23 Mn |
| Jun 30, 2025 | 188.58 Mn |
| Mar 31, 2025 | 188.15 Mn |
| Dec 31, 2024 | 167.74 Mn |
| Sep 30, 2024 | 166.84 Mn |
| Jun 30, 2024 | 165.14 Mn |
| Mar 31, 2024 | 164.73 Mn |
| Dec 31, 2023 | 113.15 Mn |
| Sep 30, 2023 | 109.23 Mn |
| Jun 30, 2023 | 106.88 Mn |
| Mar 31, 2023 | 94.83 Mn |
| Dec 31, 2022 | 80.63 Mn |
| Sep 30, 2022 | 84.69 Mn |
| Jun 30, 2022 | 74.28 Mn |
| Mar 31, 2022 | 74.16 Mn |
| Dec 31, 2021 | 72.81 Mn |
| Sep 30, 2021 | 73.54 Mn |